Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid
By IANS |
93 Views
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid. Image Source: IANS News
New Delhi, July 3 : Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials.
Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events.
Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
National Doctor s Day: Here s why doctors are more than just heroes
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Industry > Industry monitor > Healthcare
29 April 2021
Ayush 64, a poly-herbal preparation originally developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) for the treatment of Malaria, in the year 1980 and now repurposed for the treatment Covid-19, has been found to be useful in the treatment of asymptomatic, mild and moderate Covid-19 infection as an adjunct to standard care.
Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR) recently collaborated for robust multi-centre clinical trials to evaluate the safety and efficacy of Ayush 64 in the management of mild to moderate Covid-19 patients.
Clinical trials were conducted at KGMU, Lucknow; DMIMS, Wardha and BMC Covid Centre, Mumbai, involving 70 participants in each arm. Dr Chopra said Ayush 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalisation compared to the only SoC procedure, Dr Arvind Chopra, director, Centre for R
Government eases buying norms for Covid supplies
SECTIONS
Last Updated: May 11, 2021, 12:03 AM IST
Share
Synopsis
Relaxing tendering norms, the government allowed global tenders to be floated for less than ₹200 crore and bank guarantees have been waived off for all procurement. As per the changes, 100% payment of advance has been approved for critical Covid procurement and procurement on nomination basis has been permitted in case of constrained supply market.
Agencies
The department of expenditure, under the ministry of finance, has issued special instructions relating to relief operations for Covid-19 pandemic relaxing the norms.
The government on Monday announced sweeping changes to the procurement norms including allowing sourcing of the same item at different rates to ease expeditious procurement of critical equipment and medicines Covid-19 supplies.